Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcriptomics of colorectal cancer in Siriraj cohort, Thailand (RNA-Seq)

ABSTRACT: To investigate the transcriptomes in colorectal cancer patients, who were diagnosed and treated at Siriraj Hospital, Thailand, we performed gene expression profiling analysis using data obtained from RNA-seq and Nanostring platforms.

ORGANISM(S): Homo sapiens

PROVIDER: GSE220148 | GEO | 2022/12/07

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Transcriptomics of colorectal cancer in Siriraj cohort, Thailand (NanoString)

Project description:To investigate the transcriptomes in colorectal cancer patients, who were diagnosed and treated at Siriraj Hospital, Thailand, we performed gene expression profiling analysis using data obtained from RNA-seq and Nanostring platforms.

2022-12-07 | GSE220149 | GEO

Transcriptomics of colorectal cancer in Siriraj cohort, Thailand (NanoString)

Project description:Transcriptomics of colorectal cancer in Siriraj cohort, Thailand (NanoString)

| PRJNA908864 | ENA

Transcriptomics of colorectal cancer in Siriraj cohort, Thailand

Project description:Transcriptomics of colorectal cancer in Siriraj cohort, Thailand

| PRJNA908859 | ENA

Transcriptomics of colorectal cancer in Siriraj cohort, Thailand (RNA-Seq)

Project description:Transcriptomics of colorectal cancer in Siriraj cohort, Thailand (RNA-Seq)

| PRJNA908865 | ENA

Transcriptomics of colorectal cancer in Siriraj cohort, Thailand

Project description:This SuperSeries is composed of the SubSeries listed below.

2022-12-07 | GSE220150 | GEO

Transcriptomics changes in liver metastatic biopsies of colorectal carcinoma between pre-treated and acquired resistance to Cetuximab [miRNA]

Project description:Two patients who were newly diagnosed and pathologically confirmed metastatic colorectal cancer were screened for eligibility between August 2011 and December 2013 in Affiliated Hospital, Academy of Military Medical Sciences. They were treated with Cetuximab in combination with FOLFOX regimen and obtained continuous partial responses in more than six months. CT scans of liver lesions were performed every two to eight weeks. The four biopsies were evaluated by two pathologists and were confirmed that the tumor purities were greater than 50%. Each biopsy was subjected to high-throughput RNA and small RNA sequencing to obtain expression profiles of genes and miRNAs.

2019-06-20 | GSE84269 | GEO

Transcriptomics changes in liver metastatic biopsies of colorectal carcinoma between pre-treated and acquired resistance to Cetuximab [mRNA]

2019-06-20 | GSE84267 | GEO

Spatially Resolved Transcriptomics Deconvolutes Histological Prognostic Subgroups in Patients with Colorectal Cancer and Synchronous Liver Metastases

Project description:This bulk mRNA data was generated using the Nanostring ncounter platform using an io360 pancancer panel of 900 genes as part of a wider project which included spatial transcriptomic data generated using the Nanostring GeoMx platform. In this study we compared tissue surgical resected from patients with colorectal cancer and liver metastases.

2023-02-02 | GSE224235 | GEO

Colorectal liver metastasis profiles

Project description:Expression profiles of colorectal liver metastasis samples collected from Paul Brousse Hospital (France) and University Hospital Utrecht (The Netherlands). Patients are divided into a high-risk (DFS < 1 year) and a low-risk group (DFS < 1 year).

2012-11-29 | E-TABM-1112 | biostudies-arrayexpress

A Low-cost Multiplex Biomarker Assay Stratifies Colorectal Cancer Patient Samples into Clinically-relevant Subtypes: Singapore Cohort RNA-seq

Project description:Objective: In order to personalise standard therapies based on molecular profiles, we previously classified colorectal cancers (CRCs) into five distinct subtypes (CRCAssigner) and later into four consensus molecular subtypes (CMS) with different prognoses and treatment responses. For clinical application, here we developed a low-cost multiplex biomarker assay. Design: Three cohorts of primary (except one liver metastases) untreated and fresh frozen CRC samples (n=57) profiled by microarray and RNA-Seq were analyzed. A reduced 38-gene panel (CRCAssigner-38) was selected from the 786-gene CRCAssigner signature (CRCAssigner-786) using an in-house class prediction approach. A customised NanoString Technologies’ nCounter platform-based assay (NanoCRCAssigner) was developed for comparison with different classifiers (CMS subtypes), platforms (microarrays and RNA-Seq), and gene sets (CRCAssigner-38 and CRCAssigner-786). Results: NanoCRCAssigner classified samples (n=48; except those showing a mixture of subtypes) into all five CRCAssigner subtypes with overall high concordance across platforms (>87%) and with CMS subtypes (81%) irrespective of variable tumour cellularity. The association of subtypes with their known molecular (microsatellite-instable and stemness), mutational (KRAS/BRAF), and clinical characteristics (including overall survival) further demonstrated assay validity. To reduce costs, we switched from standard protocol to a low-cost protocol with a high Pearson correlation co-efficient (0.9) between protocols. Technical replicates were highly correlated (0.98).

2019-03-04 | GSE101588 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data